Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism.
Human PD-L1 inhibitor III is a peptide-based molecule. It binds to human PD-1 and inhibits PD-1/PD-L1 binding. This peptide, hPDL-1 inhibitor III has anchor residues (underlined), TEKDYRHGNIRMKLAYDL that influence binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment.
CAT No: X21207
3. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
4. Implications of ligand-receptor binding kinetics on GLP-1R signalling
5. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More